This critical evidence explains the suboptimal clinical outcomes from anti-VEGF therapy and identifies invasiveness and metabolic remodeling as alternative pathways that GBM activates to resist anti-angiogenesis therapy. This evidence concerns the gene VEGFA and glioblastoma.